Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Clinical trial NCT05801107 · UNKNOWN
Trial details
- NCT number
- NCT05801107
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-25
- Primary completion
- 2023-07-15
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.